# OnCo record locoregionally-advanced-nasopharyngeal-carcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "locoregionally-advanced-nasopharyngeal-carcinoma" ;
  schema:name "Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)"@en ;
  schema:alternateName "Locally advanced NPC"@en, "Stage III to IVA nasopharyngeal carcinoma"@en, "Non-metastatic advanced nasopharyngeal carcinoma"@en, "Endemic EBV-associated nasopharyngeal carcinoma, locoregionally advanced"@en ;
  schema:description "Locoregionally advanced nasopharyngeal carcinoma is nasopharyngeal cancer, the Epstein-Barr-virus-driven cancer behind the nose, that has grown into nearby structures or neck lymph nodes but not further. It is treated without surgery, by precise radiotherapy with cisplatin, usually after gemcitabine and cisplatin chemotherapy and in recent trials with PD-1 immunotherapy; most patients are cured."@en ;
  schema:url <https://onco.cc/cancers/locoregionally-advanced-nasopharyngeal-carcinoma/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma> ;
  schema:citation <https://doi.org/10.1056/NEJMoa1905287>, <https://doi.org/10.1200/JCO.20.03237>, <https://en.wikipedia.org/wiki/Nasopharyngeal_carcinoma> ;
  onco:tag "subtype-page", "head-and-neck" ;
  onco:related <https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/>, <https://onco.cc/cancers/nasopharyngeal/>, <https://onco.cc/cancers/hpv-positive-oropharyngeal-cancer/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/acupuncture-xerostomia/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/> ;
  onco:terms <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/head-neck-subsites/> ;
  onco:trials <https://onco.cc/trials/nct07258979/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019/>, <https://onco.cc/key-papers/paper-intergroup-0099-chemoradiotherapy-nasopharyngeal-jco-1998/>, <https://onco.cc/key-papers/paper-csco-asco-nasopharyngeal-carcinoma-guideline-jco-2021/> ;
  onco:pipeline <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/trials/nct07258979/>, <https://onco.cc/terms/plasma-ebv-dna/> ;
  onco:standardOfCare <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/terms/ebv-term/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/drugs/camrelizumab/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/trials/nct07258979/>, <https://onco.cc/terms/plasma-ebv-dna/>, <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/acupuncture-xerostomia/> .